VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2013

Nov 7, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2013-11-05

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-11-05	Common Stock	M	1400	$9.07	Acquired	340295	Direct
2013-11-05	Common Stock	S	1400	$65.64	Disposed	338895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-05	Employee Stock Option (right to buy)	$9.07	M	1400	Disposed	2013-12-10	Common Stock (1400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	300000	Indirect
Common Stock	13286	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $65.64 (range $65.37 to $65.93).

F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Common stock held in grantor retained annuity trusts.

F5: Fully vested.